Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

KAPA

KAPA News

Newswire

08:19

Kairos Pharma: D. Boral Capital Raises PT to $9 from $8.50

05:46

Kairos Pharma shares surge 10.68% premarket on positive Phase 2 trial results for ENV105 in prostate cancer showing 86% clinical benefit and 13.7-month median progression-free survival.

16:20

Kairos Pharma shares surge 11.00% after-hours on positive Phase 2 prostate cancer trial results for ENV105 showing 86% clinical benefit and no severe toxicities.

09:51

Kairos Pharma: D. Boral Capital maintains Buy, raises PT to $9 from $8.

09:35

Kairos Pharma: D. Boral Capital maintains Buy, PT raised to $9.

View More

About KAPA

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More